Description overdue on 26.02.2012

Angioprotector . Active substance - Calcium dobesilate . Doksium improves microcirculation, reduces the increased permeability of blood vessels, has a positive effect on drainage of lymphatic vessels, increases the resistance of the capillary walls, improves the elasticity of erythrocyte membranes, moderately reduces blood viscosity, slows down the process of platelet aggregation. The principle of action of a drug based on the increased activity plasma kinins . Doksium available in tablet form, in the form of capsules.

Indications:

Doksium prescribed for trophic ulcers , Diabetic retinopathy, post-thrombotic syndrome, atherosclerotic vascular lesions on the lower limbs, with peripheral edema, occlusive peripheral circulatory disorders, hemorrhoids, varicose veins, hormone-dependent bronchial asthma, "steroid" vasculitis, violation of microcirculation.

Contraindications:

Doksium not prescribe intolerance dobesilate calcium hemorrhages   (in patients receiving anticoagulants), ulcerative lesions of the digestive system, pregnancy, bleeding in the digestive tract. The drug is not prescribed until the age of 13. Breastfeeding - after consulting a doctor.

Side effect:

Allergies, dyspepsia, gastralgia, diarrhea, elevated liver enzymes.

Mode of application:

Tablets and capsules Doksium not chew, taken with meals, after meals. The drug is taken three times a day at 250 milligrams. The initial dose for acute gouty arthritis is 500 mg followed by Doksium taking 250 mg twice a day with intervals of 2 hours. If necessary, the dosage is increased up to one gram. Retinopathy: 2-3 times a day with 250 mg therapy 4-6 months, after which Doksium taken at a dose of 250-500 mg per day.

Drug Interactions:

Doksium enhances the antiplatelet effect ticlopidine . The drug increases activity of heparin, anticoagulants, corticosteroids. Doksium enhances the hypoglycemic effect of sulfonylureas. Not allowed simultaneous reception Methotrexate , Lithium preparations.